Rhenman & Partners Asset Management’s AbbVie ABBV Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.4M	Buy	96,775 +25,200	+35%	+$5.42M	2.3%	6
2026 Q1	$15.6M	Sell	71,575 -39,000	-35%	-$8.65M	1.92%	14
2025 Q4	$25.3M	Sell	110,575 -19,800	-15%	-$4.51M	2.36%	8
2025 Q3	$30.2M	Buy	130,375 +61,000	+88%	+$12.4M	3.34%	3
2025 Q2	$12.9M	Sell	69,375 -19,275	-22%	-$3.58M	1.63%	23
2025 Q1	$18.6M	Sell	88,650 -35,500	-29%	-$6.9M	2.13%	20
2024 Q4	$22.1M	Sell	124,150 -52,850	-30%	-$9.72M	2.27%	12
2024 Q3	$35M	Sell	177,000 -12,000	-6%	-$2.24M	2.84%	7
2024 Q2	$32.4M	Sell	189,000 -500	-0.3%	-$82.8K	3.11%	6
2024 Q1	$34.5M	Buy	189,500 +22,500	+13%	+$3.88M	3.27%	6
2023 Q4	$25.9M	Buy	167,000 +17,000	+11%	+$2.48M	2.59%	11
2023 Q3	$22.4M	Hold	150,000	–	–	2.41%	13
2023 Q2	$20.2M	Sell	150,000 -2,000	-1%	-$293K	2.13%	18
2023 Q1	$24M	Buy	152,000 +22,000	+17%	+$3.36M	2.64%	10
2022 Q4	$21M	Sell	130,000 -19,626	-13%	-$3.01M	2.19%	15
2022 Q3	$21.9M	Sell	149,626 -40,374	-21%	-$5.79M	2.29%	9
2022 Q2	$29.1M	Sell	190,000 -5,000	-3%	-$764K	3.31%	3
2022 Q1	$31.6M	Sell	195,000 -140,000	-42%	-$20.3M	3.12%	3
2021 Q4	$45.5M	Sell	335,000 -20,000	-6%	-$2.36M	3.03%	6
2021 Q3	$38.3M	Buy	355,000 +35,000	+11%	+$4M	2.69%	7
2021 Q2	$36M	Sell	320,000 -48,000	-13%	-$5.41M	2.45%	6
2021 Q1	$39.8M	Sell	368,000 -132,000	-26%	-$14.1M	2.78%	5
2020 Q4	$53.6M	Buy	500,000 +220,000	+79%	+$21.1M	4.37%	1
2020 Q3	$24.5M	Sell	280,000 -20,000	-7%	-$1.88M	2.18%	11
2020 Q2	$29.5M	Sell	300,000 -30,000	-9%	-$2.64M	3.18%	4
2020 Q1	$25.1M	Buy	330,000 +120,000	+57%	+$10.2M	3.52%	3
2019 Q4	$18.6M	Buy	210,000 +40,000	+24%	+$3.32M	2.04%	11
2019 Q3	$12.9M	Buy	+170,000	New	+$11.7M	1.61%	23
2019 Q2	–	Sell	-60,000	Closed	-$4.83M	–	89
2019 Q1	$4.83M	Sell	60,000 -102,415	-63%	-$8.38M	0.57%	59
2018 Q4	$15M	Buy	162,415 +32,415	+25%	+$2.85M	1.71%	23
2018 Q3	$12.3M	Buy	130,000 +60,000	+86%	+$5.69M	1.23%	38
2018 Q2	$6.49M	Sell	70,000 -136,700	-66%	-$13.4M	0.66%	56
2018 Q1	$19.6M	Buy	206,700 +50,000	+32%	+$5.49M	2.41%	10
2017 Q4	$15.2M	Buy	156,700 +16,700	+12%	+$1.57M	2.05%	19
2017 Q3	$12.4M	Buy	140,000 +5,000	+4%	+$381K	1.59%	22
2017 Q2	$9.79M	Buy	135,000 +5,000	+4%	+$336K	1.41%	26
2017 Q1	$8.47M	Buy	130,000 +15,000	+13%	+$943K	1.34%	32
2016 Q4	$7.2M	Buy	115,000 +5,000	+5%	+$305K	1.38%	28
2016 Q3	$6.94M	Buy	110,000 +40,000	+57%	+$2.59M	1.1%	33
2016 Q2	$4.33M	Sell	70,000 -60,000	-46%	-$3.66M	0.77%	52
2016 Q1	$7.43M	Sell	130,000 -116,000	-47%	-$6.47M	1.47%	28
2015 Q4	$14.6M	Buy	246,000 +36,000	+17%	+$2.07M	2.2%	7
2015 Q3	$11.4M	Sell	210,000 -23,000	-10%	-$1.5M	1.82%	20
2015 Q2	$15.7M	Buy	233,000 +13,000	+6%	+$849K	1.88%	11
2015 Q1	$12.9M	Buy	220,000 +80,000	+57%	+$4.83M	2.17%	12
2014 Q4	$9.16M	Buy	140,000 +29,000	+26%	+$1.83M	2.66%	5
2014 Q3	$6.41M	Buy	+111,000	New	+$6.16M	1.88%	12
2014 Q2	–	Sell	-85,494	Closed	-$4.39M	–	97
2014 Q1	$4.39M	Buy	+85,494	New	+$4.32M	1.32%	21

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Rhenman & Partners Asset Management's ABBV Position: Q2 2026 in Review

Rhenman & Partners Asset Management increased its AbbVie (ABBV) stake by 35% in Q2 2026, buying an estimated $5.42M and bringing the position to 96,775 shares worth $24.4M. The position accounts for 2.3% of the portfolio, ranked #6.

Rhenman & Partners Asset Management first reported a position in ABBV in Q1 2014 and has held it in 48 quarters since. The position peaked at $53.6M in Q4 2020. 4,190 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Rhenman & Partners Asset Management held 96,775 shares of AbbVie worth $24.4M as of Q2 2026.
Rhenman & Partners Asset Management bought 25,200 AbbVie shares in Q2 2026, an estimated $5.42M.
AbbVie made up 2.3% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #6 holding.
Rhenman & Partners Asset Management first reported a position in AbbVie in Q1 2014 and has held it in 48 quarters since.
Rhenman & Partners Asset Management's AbbVie position peaked at $53.6M in Q4 2020.
4,190 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.